[
  {
    "ts": "2025-07-14T23:01:00+00:00",
    "headline": "Vertex Announces Broad Reimbursement Agreement With NHS England for ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor) an Innovative Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis",
    "summary": "LONDON, July 14, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that it has reached a broad reimbursement agreement with NHS England for Vertex’s cystic fibrosis (CF) medicine ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor). This agreement comes as the National Institute for Health and Care Excellence (NICE) has issued a positive final draft recommendation for this medicine.",
    "url": "https://finance.yahoo.com/news/vertex-announces-broad-reimbursement-agreement-230100375.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "e3da970a-c6d0-3287-b720-34407452fde8",
      "content": {
        "id": "e3da970a-c6d0-3287-b720-34407452fde8",
        "contentType": "STORY",
        "title": "Vertex Announces Broad Reimbursement Agreement With NHS England for ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor) an Innovative Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis",
        "description": "",
        "summary": "LONDON, July 14, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that it has reached a broad reimbursement agreement with NHS England for Vertex’s cystic fibrosis (CF) medicine ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor). This agreement comes as the National Institute for Health and Care Excellence (NICE) has issued a positive final draft recommendation for this medicine.",
        "pubDate": "2025-07-14T23:01:00Z",
        "displayTime": "2025-07-14T23:01:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/cfe59ba218db5a8309c7302823697e28",
          "originalWidth": 480,
          "originalHeight": 252,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8Hozz8YZhFoZb0IvglQ3ew--~B/aD0yNTI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/cfe59ba218db5a8309c7302823697e28.cf.webp",
              "width": 480,
              "height": 252,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lu5FFbwRXGUjaGZRJlTEiw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/cfe59ba218db5a8309c7302823697e28.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-announces-broad-reimbursement-agreement-230100375.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-announces-broad-reimbursement-agreement-230100375.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-07-14T12:30:00+00:00",
    "headline": "Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX™, a First-in-Class Non-Opioid Treatment for Adults With Moderate-to-Severe Acute Pain",
    "summary": "BOSTON, July 14, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has been named a 2025 Breakthroughs Innovation Celebration winner by Premier, Inc., a leading health care improvement company. The honor recognizes JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain, as a groundbreaking health care technology.",
    "url": "https://finance.yahoo.com/news/vertex-named-premier-inc-breakthroughs-123000522.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "f9e20ba3-649a-3cdd-b63c-fcc99b723614",
      "content": {
        "id": "f9e20ba3-649a-3cdd-b63c-fcc99b723614",
        "contentType": "STORY",
        "title": "Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX™, a First-in-Class Non-Opioid Treatment for Adults With Moderate-to-Severe Acute Pain",
        "description": "",
        "summary": "BOSTON, July 14, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has been named a 2025 Breakthroughs Innovation Celebration winner by Premier, Inc., a leading health care improvement company. The honor recognizes JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain, as a groundbreaking health care technology.",
        "pubDate": "2025-07-14T12:30:00Z",
        "displayTime": "2025-07-14T12:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/5666cd199a664274516f30c5e5ec9274",
          "originalWidth": 480,
          "originalHeight": 252,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/N9sL_3NsAW3I4uzXHpy_oA--~B/aD0yNTI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/5666cd199a664274516f30c5e5ec9274.cf.webp",
              "width": 480,
              "height": 252,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kGvoOefvCuyhWIYQfmYIPw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/5666cd199a664274516f30c5e5ec9274.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-named-premier-inc-breakthroughs-123000522.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-named-premier-inc-breakthroughs-123000522.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PINC"
            },
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-07-14T08:44:00+00:00",
    "headline": "My 3 Top Stocks to Buy in a Market That's Highly Volatile (Again)",
    "summary": "Dominion Energy is the kind of stable utility stock that's great to own during turbulent markets.  Enbridge has a lower risk than ever before with its midstream and natural gas utility businesses.  Vertex Pharmaceuticals boasts a strong cystic fibrosis franchise along with exciting new products and pipeline candidates.",
    "url": "https://www.fool.com/investing/2025/07/14/my-3-top-stocks-to-buy-in-a-market-thats-highly-vo/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "a3aaf597-3529-3ddd-bc3a-8dea1d424d33",
      "content": {
        "id": "a3aaf597-3529-3ddd-bc3a-8dea1d424d33",
        "contentType": "STORY",
        "title": "My 3 Top Stocks to Buy in a Market That's Highly Volatile (Again)",
        "description": "",
        "summary": "Dominion Energy is the kind of stable utility stock that's great to own during turbulent markets.  Enbridge has a lower risk than ever before with its midstream and natural gas utility businesses.  Vertex Pharmaceuticals boasts a strong cystic fibrosis franchise along with exciting new products and pipeline candidates.",
        "pubDate": "2025-07-14T08:44:00Z",
        "displayTime": "2025-07-14T08:44:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/1617f7aa4d70c01464e26d6704c7aa44",
          "originalWidth": 1400,
          "originalHeight": 934,
          "caption": "A road sign stating \"Volatility Ahead\" with clouds in the background.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IAD9xZN4sagkeKt_Mjs9iQ--~B/aD05MzQ7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/1617f7aa4d70c01464e26d6704c7aa44.cf.webp",
              "width": 1400,
              "height": 934,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BYlbLmd4BWv5qfY6xbG_sQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/1617f7aa4d70c01464e26d6704c7aa44.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/07/14/my-3-top-stocks-to-buy-in-a-market-thats-highly-vo/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/3-top-stocks-buy-market-084400401.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ENB.TO"
            },
            {
              "symbol": "D"
            },
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]